Charles Schwab Investment Management Inc. Has $14.75 Million Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Charles Schwab Investment Management Inc. grew its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 2.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,155,080 shares of the biopharmaceutical company’s stock after purchasing an additional 32,347 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.88% of Dynavax Technologies worth $14,750,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in DVAX. Smartleaf Asset Management LLC raised its holdings in shares of Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares during the period. GAMMA Investing LLC raised its holdings in shares of Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Dynavax Technologies during the fourth quarter valued at about $71,000. Nisa Investment Advisors LLC raised its holdings in shares of Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 1,076 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Dynavax Technologies during the third quarter valued at about $89,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Trading Down 0.1 %

DVAX opened at $13.62 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The firm has a market capitalization of $1.69 billion, a PE ratio of 75.67 and a beta of 1.23. The company’s 50-day moving average is $13.19 and its 200 day moving average is $12.37.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The business had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. As a group, research analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on DVAX shares. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. HC Wainwright restated a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st. The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. Finally, William Blair restated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.